New York, NY, United States
New York, NY, United States

Anavex Life Sciences Corp. is a pharmaceutical company that develops drug candidates.ANAVEX 2-73 has been shown to provide protection from oxidative stress, which damages and destroys neurons and is believed to be a primary cause of Alzheimer's disease. Research in recent years indicates that oxidative stress is a precursor to amyloid-beta plaques and tau , and could be a novel and appropriate therapeutic target. Wikipedia.


Time filter

Source Type

News Article | November 16, 2016
Site: www.eurekalert.org

Today, senior representatives from the U.S. Food and Drug Administration (FDA) and the National Institute on Aging (NIA) at the National Institutes of Health (NIH) joined with advocates, federal colleagues, researchers, and industry to explore collaborations for advancing the most up-to-date knowledge in Alzheimer's disease research into clinical trials at the ACT-AD Coalition's Ninth Annual FDA/Alzheimer's Disease Allies Meeting in North Bethesda, Md. The theme of this year's meeting was "Starting with the End in Mind: Aligning the Science to Close Gaps in Alzheimer's Disease Therapeutic Development." "Our 2015 ACT-AD meeting focused on the state of research, including existing gaps, into the underlying causes of Alzheimer's disease and the pathways for successful treatment. This year, we picked up where that meeting left off," says ACT-AD Executive Director Cynthia Bens. "At our meeting today, attendees held a frank discussion on whether NIH research is on track to help definitively close knowledge gaps identified by the FDA that will promote more successful therapeutic development. The consensus is that we have made significant strides, but we need to continue to refine strategies that increase research collaborations between government agencies, researchers, advocates, and industry. We look forward to continuing to build on the progress we made today." The main areas of focus at the meeting included: the most recent research on Alzheimer's disease pathology and genetics; efforts to identify reliable biomarkers in treatment trials and advance novel biomarkers; and symptomatic approaches to improve treatment of major behavioral and psychiatric aspects of the disease. Also, a distinguished panel of experts explored the scientific and regulatory considerations for developing meaningful disease-modifying and symptomatic Alzheimer's disease treatments. ACT-AD and its partners will provide a more detailed summary of the results of today's meeting at a future date. ACT-AD is a coalition of more than 50 national organizations representing patients, providers, caregivers, consumers, older Americans, researchers, and employers seeking to accelerate development of potential cures and treatments for Alzheimer's disease. The coalition is directed by an Advisory Council made up of representatives from the Alliance for Aging Research (AAR), Alzheimer's Foundation of America (AFA), American Society on Aging (ASA), National Alliance for Caregiving (NAC), National Association of Area Agencies on Aging (n4a), National Consumers League (NCL), Research!America, and the Society for Women's Health Research. The coalition is sponsored in part by Alkermes, Anavex, Avanir, Axovant, Biogen Idec, Eli Lilly, Genentech, Janssen, Lundbeck, Merck, and Novartis.


Today, senior representatives from the U.S. Food and Drug Administration (FDA) and the National Institute on Aging (NIA) at the National Institutes of Health (NIH) joined with advocates, federal colleagues, researchers, and industry to explore collaborations for advancing the most up-to-date knowledge in Alzheimer’s disease research into clinical trials at the ACT-AD Coalition's Ninth Annual FDA/Alzheimer’s Disease Allies Meeting in North Bethesda, Md. The theme of this year’s meeting was "Starting with the End in Mind: Aligning the Science to Close Gaps in Alzheimer’s Disease Therapeutic Development." “Our 2015 ACT-AD meeting focused on the state of research, including existing gaps, into the underlying causes of Alzheimer’s disease and the pathways for successful treatment. This year, we picked up where that meeting left off,” says ACT-AD Executive Director Cynthia Bens. “At our meeting today, attendees held a frank discussion on whether NIH research is on track to help definitively close knowledge gaps identified by the FDA that will promote more successful therapeutic development. The consensus is that we have made significant strides, but we need to continue to refine strategies that increase research collaborations between government agencies, researchers, advocates, and industry. We look forward to continuing to build on the progress we made today.” The main areas of focus at the meeting included: the most recent research on Alzheimer’s disease pathology and genetics; efforts to identify reliable biomarkers in treatment trials and advance novel biomarkers; and symptomatic approaches to improve treatment of major behavioral and psychiatric aspects of the disease. Also, a distinguished panel of experts explored the scientific and regulatory considerations for developing meaningful disease-modifying and symptomatic Alzheimer’s disease treatments. ACT-AD and its partners will provide a more detailed summary of the results of today’s meeting at a future date. For more information, please visit the coalition’s meeting webpage or call 202-688-1229. ACT-AD is a coalition of more than 50 national organizations representing patients, providers, caregivers, consumers, older Americans, researchers, and employers seeking to accelerate development of potential cures and treatments for Alzheimer's disease. The coalition is directed by an Advisory Council made up of representatives from the Alliance for Aging Research (AAR), Alzheimer's Foundation of America (AFA), American Society on Aging (ASA), National Alliance for Caregiving (NAC), National Association of Area Agencies on Aging (n4a), National Consumers League (NCL), Research!America, and the Society for Women's Health Research. The coalition is sponsored in part by Alkermes, Anavex, Avanir, Axovant, Biogen Idec, Eli Lilly, Genentech, Janssen, Lundbeck, Merck, and Novartis.


NEW YORK, Dec. 12, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for its fiscal year ended September 30, 2016. “We are entering into 2017 with a stronger balance sheet and a strengthened corporate and scientific advisory team coupled with recently reported encouraging 57-week safety and tolerability data for ANAVEX 2-73, which restores cellular homeostasis, in a Phase 2a clinical trial in Alzheimer’s disease,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “We are now analyzing the significant correlations observed between cognition, function and behavior in combination with PK/PD modeling of the population as well as of each individual patient in order to derive the optimal parameters for the subsequent planned placebo-controlled efficacy trials. We believe this coherent approach should reduce future clinical development risk.” Dr. Missling continued, “Given the strengthened financial resources and scientific validation, in 2017, we are able to prepare for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX 2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.” Financial information for the fiscal year ended September 30, 2016 should be read in conjunction with the Company’s audited consolidated financial statements, which will appear on EDGAR and will be available on the Anavex website at www.anavex.com. To join the conference call, dial the toll-free number: (866) 939-3921. Please use confirmation number 43930140, followed by the pound sign (#). The live webcast of the conference call can be accessed online at http://wsw.com/webcast/cc/avxl. Investors may also listen to an archived version of the webcast on www.anavex.com. Anavex Life Sciences Corp. (Nasdaq:AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX 2-73, is currently in a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX 2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors and successfully completed Phase 1 with a clean safety profile. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex a research grant to develop ANAVEX 2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX 2-73 into a Parkinson’s disease clinical trial. ANAVEX 3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions. Further information is available at www.anavex.com. Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.


NEW YORK, Dec. 08, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL) today announced a positive 57-week update from its Phase 2a study in mild-to-moderate Alzheimer’s disease (AD) patients for ANAVEX 2-73, which targets cellular homeostasis. The study met both primary and secondary endpoints. At 57 weeks, Alzheimer’s patients taking a daily oral dose between 10mg and 50mg, ANAVEX 2-73 was well tolerated. There were no clinically significant treatment-related adverse events and no serious adverse events. Published AD studies confirmed substantial declines of cognitive (MMSE) and functional (ADCS-ADL) measures as well as Cogstate and EEG/ERP over 12 month in similar AD populations. Pre-specified exploratory analyses of the current study included the cognitive (MMSE) and the functional (ADCS-ADL) as well as Cogstate, HAM-D and EEG/ERP changes from baseline. Specifically, in comparison to historical control from a pooled placebo arm cohort study conducted by the Alzheimer Disease Cooperative Study Group in mild-to-moderate AD patients of comparable ages and MMSE baselines, over 12 month the ANAVEX 2-73 data shows a calculated treatment benefit of 1.8 points on the MMSE scale (p<0.016) and a calculated treatment benefit of 4 points on the ADCS-ADL score (p<0.019). Furthermore, the correlation was positive with all measured scores (MMSE, ADCS-ADL, Cogstate, HAM-D and EEG/ERP). George Perry, PhD, Dean and Professor at the University of Texas at San Antonio and Editor-in Chief of the Journal of Alzheimer’s Disease, commented, “In addition to the very encouraging results, which point to the therapeutic potential of targeting cellular homeostasis in a complex CNS disease like Alzheimer’s, this trial has been intelligently designed as a highly informative study, looking unprejudiced at all potential relationships and hence allowing to learn from all correlations of the now available pool of data, in order to execute subsequent trials with much more relevant information at hand.” Despite non-optimized dosing of ANAVEX 2-73 throughout the 12-month study, continued significant improvements from baseline of cognitive, functional and behavioral scores in a group of patients were observed, respectively. This data will be analyzed using refined mathematical modeling methods in conjunction with the detailed pharmacokinetic (PK) information. “Alzheimer’s disease is a progressive neurodegenerative disease that causes problems with memory, thinking and behavior. Currently available treatments cannot stop Alzheimer's from progressing; they can only temporarily slow the worsening of dementia symptoms,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. "We believe this data gives us a solid foundation from which to continue the next phase of rationally designed clinical trials. Anavex is grateful for the dedication of the patients, their families and the clinical investigators who participated in this study." The Company is presenting findings from the study at the Clinical Trials on Alzheimer's Disease (CTAD) meeting on Saturday, December 10th at 8:45 a.m. PT in the oral communication session. The presentation will be available in the publications section of the Anavex website. The Company will also conduct a conference call with the investment community in conjunction with the upcoming financial year-end 2016 report. About the ANAVEX 2-73 Phase 2a Study  The multicenter Phase 2a clinical trial of ANAVEX 2-73 consists of two parts and a total of 32 mild-to-moderate Alzheimer’s patients. PART A is a simple randomized, open-label, two-period, cross-over between oral (30mg/50mg) and IV (3mg/5mg) administration, adaptive trial lasting up to 5 weeks for each patient. PART B is an open-label extension for an additional 52 weeks. Initially planned for 26 weeks, PART B was extended to 52 weeks as a result of requests from patients and caregivers. The primary endpoint of the Phase 2a trial is to establish safety, tolerability and maximum tolerated dose (MTD) of ANAVEX 2-73, which had shown potential in preclinical studies to prevent, halt and/or reverse the course of the disease. Secondary endpoints include dose response, bioavailability, and exploratory cognitive as well as functional measures using Mini Mental State Examination (MMSE) and evaluation of Alzheimer’s Disease Co-operative Study – Activities of Daily Living Inventory (ADCS-ADL), as well as Cogstate test battery and EEG/ERP. Additional information regarding the ongoing Phase 2a clinical trial is available from the U.S. National Institutes of Health (NIH) clinical trials database at www.clinicaltrials.gov. About CTAD 2016 The International Conference on Clinical Trials for Alzheimer’s Disease (CTAD) is an annual conference organized and planned by Alzheimer’s disease clinical researchers to share scientific information with each other. The 9th annual CTAD 2016 will be held December 8-10 in San Diego, CA. Further information is available at http://www.ctad-alzheimer.com/. About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (Nasdaq:AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX 2-73, is currently in a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX 2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors and successfully completed Phase 1 with a clean safety profile. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. ANAVEX 3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions. Further information is available at www.anavex.com. Forward-Looking Statements Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.


— Amyotrophic Lateral Sclerosis Pipeline Market Companies Involved in Therapeutics Development are 2-BBB Medicines BV, AB Science SA, Aestus Therapeutics Inc, Anavex Life Sciences Corp, Angion Biomedica Corp, Apodemus AB, Apogenix GmbH, Apotex Inc, ArmaGen Inc, BioCrea GmbH, Biogen Inc, Biohaven Pharmaceutical Holding Company Limited, BioHealthonomics Inc, BrainStorm Cell Therapeutics Inc, Calico LLC, Catabasis Pharmaceuticals Inc, Cellceutix Corp, Chronos Therapeutics Ltd, ContraVir Pharmaceuticals Inc, Corcept Therapeutics Inc, Curatis Pharma GmbH, Cytokinetics Inc, Daval International Ltd, Edison Pharmaceuticals Inc, Eisai Co Ltd, Ensemble Therapeutics Corp, Evotec AG, F. Hoffmann-La Roche Ltd, Flex Pharma, Inc., FPRT Bio Inc, Gemac, Genentech Inc, Genervon Biopharmaceuticals LLC, GeNeuro SA, GenKyoTex SA, Glialogix Inc, Grifols SA, Herantis Pharma Plc, ImStar Therapeutics Inc., InFlectis BioScience, Ionis Pharmaceuticals Inc, Italfarmaco SpA, Jeil Pharmaceutical Co Ltd, Kadimastem Ltd, Karyopharm Therapeutics Inc, KineMed Inc, Kringle Pharma Inc, Kyorin Pharmaceutical Co Ltd, Kyowa Hakko Kirin Co Ltd, Lascco SA, Lead Discovery Center GmbH, M's Science Corp, Maas Biolab, Mallinckrodt Plc, MedDay SA, MeiraGTx Limited, miCure Therapeutics Ltd., miRagen Therapeutics Inc, MitoDys Therapeutics Limited, Mitsubishi Tanabe Pharma Corp, Neuralstem Inc, Neuraltus Pharmaceuticals Inc, Neurimmune Holding AG, Neurotec Pharma SL, Neurotune AG, Orion Oyj, Orphazyme ApS, Pharnext SA, Plex Pharmaceuticals Inc, Prevacus Inc, Primary Peptides, Inc., ProMIS Neurosciences Inc, Q Therapeutics Inc, ReceptoPharm Inc, Regenesance BV, reMYND NV, Saneron CCEL Therapeutics Inc, SciFluor Life Sciences LLC, SK Biopharmaceuticals Co Ltd, Spherium Biomed SL, Symic Biomedical Inc, Teva Pharmaceutical Industries Ltd, Thera Neuropharma Inc, Treeway BV, Valeant Pharmaceuticals International Inc, ViroMed Co Ltd, VivaCell Biotechnology Espana SL, Voyager Therapeutics Inc, WAVE Life Sciences Ltd and Yooyoung Pharmaceutical Co Ltd. This research provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Inquire more about this research at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=774107 The Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 2, 23, 12, 2, 74, 25 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 42 and 9 molecules, respectively. Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Buy a copy of this research report at http://www.reportsnreports.com/purchase.aspx?name=774107 • The pipeline guide provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis (Central Nervous System). • The pipeline guide reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System) • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. • Find and recognize significant and varied types of therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System). • Classify potential new clients or partners in the target demographic. • Develop tactical initiatives by understanding the focus areas of leading companies. • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. • Formulate corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics. • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. For more information, please visit http://www.reportsnreports.com/reports/774107-amyotrophic-lateral-sclerosis-pipeline-review-h2-2016.html


NEW YORK, Nov. 28, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced the appointment of three distinguished researchers to its Scientific Advisory Board. Dr. Simuni earned her Bachelor of Science and medical degrees from Leningrad Medical School, Russia. She completed a neurology residency and clinical neurophysiology fellowship at Temple University, Philadelphia, and a fellowship in movement disorders at the University of Pennsylvania, Philadelphia. She joined the neurology faculty at Northwestern University in 2000. She has built a multidisciplinary Parkinson’s disease center that has been designated a Center of Excellence by the National Parkinson’s Foundation. Dr. Simuni’s research interests include experimental pharmacology, early diagnosis, non-motor manifestations and surgical management of Parkinson’s disease. As principal or co-investigator of numerous NINDS, MJFF and industry sponsored clinical trials, Dr. Simuni has done extensive research on the treatment of Parkinson’s disease focused on studying potential disease modifying strategies. Dr. Simuni is the principal investigator on the NINDS-funded, multicenter Phase III study of the potential disease modifying agent, isradipine. Dr. Simuni has received several prestigious awards including the Dixon Foundation Innovation Award, National Parkinson’s Foundation Research Awards, Northwestern Department of Neurology Teacher of the Year Award, and the Northwestern Medical Foundation Award for Excellence in Clinical Leadership. Dr. Simuni dedicates substantial amount of her professional time to teaching and mentoring, and has served as the neurology residency program director at Northwestern. Dr. Weintraub is professor of psychiatry and neurology at Penn and psychiatrist at the Parkinson’s Disease Research, Education and Clinical Center (PADRECC) at the Philadelphia Veterans Affairs Medical Center. A geriatric psychiatrist, he conducts clinical research in the psychiatric and cognitive complications of Parkinson’s disease, and is author of more than 100 journal articles, reviews, and book chapters. He completed a NIMH Career Development Award titled “Depression Diagnosis and Treatment in Parkinson Disease”, and has been PI on grants from the VA, Penn, The Michael J. Fox Foundation for Parkinson’s Research, and several industry-sponsored studies, and is current Clinical Core Leader of the Penn Udall Center focused on cognition in Parkinson’s disease. Dr. Weintraub is Associate Editor for Movement Disorders journal, formerly was on the Executive Committee of the Parkinson Study Group (PSG), has been a member of four Movement Disorder Society (MDS) task forces to revise and make recommendations for the assessment of cognitive and psychiatric symptoms in Parkinson’s disease, and was chair of the Psychiatry Subgroup of the NINDS Common Data Elements (CDE) project. Dr. Kalpana Merchant has deep expertise in the neurobiology of chronic neurodegenerative and psychiatric disorders. She has nearly 25 years of experience in drug discovery and development with a special emphasis on translational strategies that improve the success rate of drug development. In March 2014, Kalpana established a life sciences business that provides consultancy services to non-profit institutions and start-up pharmaceutical/ biotechnology companies. She continues to remain engaged in training and mentoring of graduate students, postdoctoral scientists and junior faculty through her academic positions. Prior to her consulting activities, Kalpana worked in the US pharmaceutical industry as a scientific contributor and in strategic leadership/ management roles. She retired in March 2014 from Eli Lilly and Company where she was the Chief Scientific Officer for Tailored Therapeutics - Neuroscience, accountable for scientific and business strategies to deliver personalized therapies and associated biomarkers for the neuroscience portfolio – from discovery through Phase III. Kalpana received her PhD in neuropharmacology from the University of Utah. Following a postdoctoral research fellowship at University of Washington, she was appointed Assistant Professor of Psychiatry at the same institution. She was recruited to Eli Lilly in 2003 from Pharmacia Corp., where she had contributed to neuroscience drug discovery research for 10 years. Kalpana is engaged in the wider scientific community via her service on the National Center for Advancing Translational Sciences (NCATS) Advisory Council and the Cures Acceleration Network Review Board for the National Institutes of Health (NIH), as an advisor to the Michael J Fox Foundation for Parkinson’s Research, membership of The Wellcome Trust Review Board as well as several professional societies. “We are pleased to welcome Drs. Tanya Simuni, Daniel Weintraub and Kalpana Merchant to Anavex’s Scientific Advisory Board,” stated Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “These world-renowned researchers bring extensive experience in neurological diseases to Anavex. I am confident they will make important contributions to our SAB and to the continued development of ANAVEX 2-73 and other compounds in our pipeline for the treatment of neurodegenerative diseases, including Parkinson’s disease.” Anavex Life Sciences Corp. (Nasdaq:AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX 2-73, is currently in a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX 2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors and successfully completed Phase 1 with a clean safety profile. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex a research grant to develop ANAVEX 2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX 2-73 into a Parkinson’s disease clinical trial. ANAVEX 3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions. Further information is available at www.anavex.com. Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.


NEW YORK, Dec. 01, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL) today announced that Christopher U. Missling, Ph.D., President and Chief Executive Officer, will participate on a panel comprising 14 representatives from government and industry at the Fourth Annual Mental Health Parity and Addiction Equity Act (MHPAEA) Business Roundtable. The panel members will discuss the current challenges around implementation of the Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008 and an action plan. The event will take place on Tuesday, December 6, 2016, at the U.S. Capitol Visitor Center, in Washington, D.C. “There is an unmet medical need around brain illnesses such as Traumatic Brain Injury (TBI) and Post Traumatic Stress Disorder (PTSD) that must be overcome especially given its impact on our veterans while addressing two daunting complexities: the biology of the brain and resources,” said E. Teresa Touey, organizer of the MHPAEA Business Roundtable. “As a panelist, Dr. Missling brings relevant drug development experience in complex diseases like Alzheimer’s, Parkinson’s, Rett syndrome, and other neurological disorders, so the work that Anavex is doing is immensely important.” About the Mental Health Parity and Addiction Equity Act (MHPAEA) The Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA) requires group health plans and health insurance issuers to ensure that financial requirements (such as co-pays, deductibles) and treatment limitations (such as visit limits) applicable to mental health or substance use disorder (MH/SUD) benefits are no more restrictive than the predominant requirements or limitations applied to substantially all medical/surgical benefits. MHPAEA supplements prior provisions under the Mental Health Parity Act of 1996 (MHPA), which required parity with respect to aggregate lifetime and annual dollar limits for mental health benefits. Anavex Life Sciences Corp. (Nasdaq:AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX 2-73, is currently in a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX 2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors and successfully completed Phase 1 with a clean safety profile. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex a research grant to develop ANAVEX 2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX 2-73 into a Parkinson’s disease clinical trial. ANAVEX 3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions. Further information is available at www.anavex.com. Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.


NEW YORK, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL) today reported encouraging preclinical efficacy for the treatment of neuropathic pain and visceral pain with their novel compound, ANAVEX 1066. The poster titled “Mixed sigma-1 / sigma-2 ligands as analgesics: studies with ANAVEX 1066 in animal models of neuropathic pain and visceral pain” was presented at the annual meeting of the Society for Neuroscience taking place from November 12-16 in San Diego, California. ANAVEX 1066 was tested in two models of neuropathic and visceral pain that have been extensively validated in rats.  In the chronic constriction injury (CCI) model of neuropathic pain, a single oral administration of ANAVEX 1066 dose-dependently restored the nociceptive threshold in the affected paw to normal levels while leaving the contralateral healthy paw unchanged. Efficacy was rapid and remained significant for two hours. In a model of visceral pain, chronic colonic hypersensitivity was induced by injection of an inflammatory agent directly into the colon and a single oral administration of ANAVEX 1066 returned the nociceptive threshold to control levels in a dose-dependent manner. Companion studies in rats demonstrated the lack of any effects on normal gastrointestinal transit with ANAVEX 1066 and a favorable safety profile in a battery of behavioral measures. Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, stated, “The therapeutic potential of ANAVEX 1066 in two distinct and poorly served populations, patients with neuropathic pain and patients with visceral pain, is encouraging and we look forward to advancing the program for ANAVEX 1066.” The poster presentation is available on the Publications page of Anavex’s website at http://www.anavex.com/publications/. Neuropathic pain is caused by damage to or disease affecting the somatosensory nervous system. Neuropathic pain may be associated with a heightened response to normal pain stimuli (hyperalgesia) or pain from normally non-painful stimuli (allodynia). It may have continuous and/or episodic (paroxysmal) components, the latter resemble stabbing sensations or electric shocks. General population studies, using validated screening instruments, have estimated that 7–8% of adults currently have chronic pain with neuropathic characteristics. Visceral pain results from the activation of nociceptors of the thoracic, pelvic, or abdominal viscera. Visceral pain is diffuse, difficult to localize and often considered by patients to have a deep, sickening component. It may be accompanied by symptoms such as nausea, vomiting, and changes in vital signs as well as emotional manifestations. Irritable bowel syndrome (IBS), a dysfunctional condition causing recurrent attacks of abdominal pain, has been estimated to affect 25% of the population in many countries and accounts for 40–50% of all gastroenterologic consultations worldwide. ANAVEX 1066, a mixed Sigma-1/Sigma-2 receptor ligand, has previously demonstrated antitumor activity as well as analgesic effects in an animal model of chemotherapy-induced polyneuropathy. Current therapies for neuropathic and visceral pain are not satisfactory and thus new drugs acting on novel molecular targets are actively being investigated. Anavex Life Sciences Corp. (Nasdaq:AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX 2-73, is currently in a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX 2-73 is an orally available drug candidate that targets sigma-1 and muscarinic receptors and successfully completed Phase 1 with a clean safety profile. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex a research grant to develop ANAVEX 2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX 2-73 into a Parkinson’s disease clinical trial. ANAVEX 3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions. Further information is available at www.anavex.com. Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Loading Anavex collaborators
Loading Anavex collaborators